Genocea Biosciences Inc at American Association for Cancer Research (AACR) Investor Webinar Transcript
Good afternoon, everyone. Thank you for joining us today to talk about the initial clinical data from our TITAN study for GEN-011, our new kind of Autologous T cell therapy for the treatment of solid tumors.
Before I get into the bulk of the story, I'm going to just remind the audience that I will -- I and we will be making forward-looking statements today. And -- so please take note of that fact.
Let me provide you first and foremost with the bottom line, which is as follows: We have in hand some very promising initial findings from the first 5 patients dosed in our TITAN study. Specifically, we have consistently shown monotherapy clinical activity in very, very sick patients with checkpoint-refractory progressive disease. We also have a safety and tolerability profile that is acceptable in this context. And very importantly, we are already showing that our PLANET process for the production of GEN-011 lives up to its billing as highly reliable and applicable to any patient.
But as excited as we are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
